Last reviewed · How we verify
Conventional-dose Atorvastatin
At a glance
| Generic name | Conventional-dose Atorvastatin |
|---|---|
| Also known as | Lipitor |
| Sponsor | Beijing Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Early Combined Therapy With PCSK9 Inhibitors and Statins in Acute Ischemic Stroke (PHASE2, PHASE3)
- Weak Pulse at Yang and Wiry Pulse at Yin Theory (NA)
- Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial (NA)
- Ultra-early STatin in Patients With Aneurysmal subaRachnoid Hemorrhage (Ue-STAR) (PHASE3)
- Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial). (PHASE4)
- Efficacy of Phentolamine in Prevention of Contrast-Associated Acute Kidney Injury After Complex PCI (PHASE2, PHASE3)
- Effect of Intensive LDL-cholesterol Targeting for Elderly Patients With Cardiovascular Disease: I-OLD Trial (PHASE4)
- Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Conventional-dose Atorvastatin CI brief — competitive landscape report
- Conventional-dose Atorvastatin updates RSS · CI watch RSS
- Beijing Hospital portfolio CI